Allink Biotherapeutics Secures $47 Million Series A Funding to Advance Clinical Programs and Innovative Platforms Allink Biotherapeutics has successfully raised $47 million in a Series A funding round led by Legend Capital and Meituan Long-Z Investment to advance its clinical programs and research.

Allink Biotherapeutics Secures $47 Million Series A Funding to Advance Clinical Programs and Innovative Platforms #Shanghai #USA #ADC #Series_A #Allink_Bio